Talabostat, fibroblast activation protein inhibitor, attenuates inflammation and fibrosis in systemic sclerosis
Inflammopharmacology · 2024
DOI: 10.1007/s10787-024-01536-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammopharmacology, 2024. Verfasst von Mehrnoosh Pashaei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Fibroblasts, Fibrosis, Inflammation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Tehran University of Medical Sciences and Health Services.
Abstract (Originalsprache)
BACKGROUND: Systemic sclerosis (SSc) is a connective tissue disorder characterized by excessive fibrosis, where activated fibroblasts play a pivotal role in disease progression. This study aimed to investigate the potential of Talabostat, a small molecule inhibitor of dipeptidyl peptidases, in alleviating fibrosis and inflammation associated with SSc pathogenesis. METHODS: Dermal fibroblasts were obtained from skin biopsies of ten diffuse cutaneous SSc patients and healthy controls. These fibroblasts were subjected to treatment with either TGF-β alone or in combination with Talabostat. Immunofluorescence staining was conducted to evaluate FAPα and α-SMA protein levels. The expression of activated fibroblast markers (FAPα and ACAT2), pro-fibrotic (COL1A1 and COL1A2), anti-fibrotic (MMP1, MMP2, and MMP9), and inflammatory (IL-6 and TGFβ1) related genes was measured by quantitative real-time PCR. Talabostat-treated fibroblasts were assessed for their migratory capacity using a scratch assay and for their viability through MTT assay and Annexin V staining. RESULTS: The basal expression of COL1A1 and TGFβ1 was notably higher in healthy subjects, while MMP1 expression showed a significant increase in SSc patients. Furthermore, TGF-β stimulation led to upregulation of activated fibroblast markers, pro-fibrotic, and inflammatory-related genes in SSc-derived fibroblasts, which were attenuated upon Talabostat treatment. Interestingly, Talabostat treatment resulted in an upregulation of MMP9 expression. Moreover, Talabostat exhibited a concentration-dependent inhibition of activated fibroblast viability in both healthy and SSc fibroblasts, and suppressed fibroblast migration specifically in SSc patients. CONCLUSION: In summary, Talabostat modulates fibrotic genes in SSc, thereby inhibiting myofibroblast differentiation, activation, and migration. These findings suggest promising therapeutic avenues for targeting fibrosis in SSc.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- Research Center for Chronic Inflammatory Diseases, Tehran University of Medical Sciences, Tehran, Iran.
- Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran. mahmoudim@tums.ac.ir.
- Rheumatology Research Center, Tehran University of Medical Sciences, Shariati Hospital, Kargar Ave, P.O. BOX: 1411713137, Tehran, Iran. mahmoudim@tums.ac.ir.
- Research Center for Chronic Inflammatory Diseases, Tehran University of Medical Sciences, Tehran, Iran. mahmoudim@tums.ac.ir.
Förderung
- Tehran University of Medical Sciences and Health Services
Zitieren
APA
Pashaei, M., Farhadi, E., Kavosi, H., Madreseh, E., Enayati, S., Mahmoudi, M., & Amirzargar, A. (2024). Talabostat, fibroblast activation protein inhibitor, attenuates inflammation and fibrosis in systemic sclerosis. Inflammopharmacology. https://doi.org/10.1007/s10787-024-01536-6
Vancouver
Pashaei M, Farhadi E, Kavosi H, Madreseh E, Enayati S, Mahmoudi M, et al. Talabostat, fibroblast activation protein inhibitor, attenuates inflammation and fibrosis in systemic sclerosis. Inflammopharmacology. 2024. doi:10.1007/s10787-024-01536-6
BibTeX
@article{Pashaei2024,
author = {Pashaei, Mehrnoosh and Farhadi, Elham and Kavosi, Hoda and Madreseh, Elham and Enayati, Samaneh and Mahmoudi, Mahdi and Amirzargar, Aliakbar},
title = {Talabostat, fibroblast activation protein inhibitor, attenuates inflammation and fibrosis in systemic sclerosis},
journal = {Inflammopharmacology},
year = {2024},
doi = {10.1007/s10787-024-01536-6}
}
EUVIMED